Entrada Therapeutics (TRDA) EBIAT (2022 - 2025)
Historic EBIAT for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$44.1 million.
- Entrada Therapeutics' EBIAT fell 21452.39% to -$44.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.5 million, marking a year-over-year decrease of 28826.77%. This contributed to the annual value of $65.6 million for FY2024, which is 108169.04% up from last year.
- Entrada Therapeutics' EBIAT amounted to -$44.1 million in Q3 2025, which was down 21452.39% from -$43.1 million recorded in Q2 2025.
- Entrada Therapeutics' 5-year EBIAT high stood at $55.0 million for Q2 2024, and its period low was -$44.1 million during Q3 2025.
- Moreover, its 4-year median value for EBIAT was -$17.3 million (2025), whereas its average is -$9.4 million.
- Per our database at Business Quant, Entrada Therapeutics' EBIAT surged by 45205.27% in 2024 and then plummeted by 21452.39% in 2025.
- Over the past 4 years, Entrada Therapeutics' EBIAT (Quarter) stood at -$24.6 million in 2022, then skyrocketed by 61.25% to -$9.5 million in 2023, then surged by 111.85% to $1.1 million in 2024, then crashed by 4002.21% to -$44.1 million in 2025.
- Its EBIAT stands at -$44.1 million for Q3 2025, versus -$43.1 million for Q2 2025 and -$17.3 million for Q1 2025.